Rituximab plus lenalidomide demonstrates long-lasting responses and improved outcomes as first-line therapy for follicular lymphoma, according to a phase 2 trial.
Rituximab plus lenalidomide demonstrates long-lasting responses and improved outcomes as first-line therapy for follicular lymphoma, according to a phase 2 trial.
Plasma cytokines and chemokine levels may be used as predictive biomarkers of CAR-T therapy response and toxicity among patients with large B-cell lymphoma.
Plasma cytokines and chemokine levels may be used as predictive biomarkers of CAR-T therapy response and toxicity among patients with large B-cell lymphoma.
Treatment for relapsed/refractory diffuse large B-cell lymphoma with odronextamab demonstrated a manageable safety profile and durable responses among patients previously treated with 2 lines of therapy.
Treatment for relapsed/refractory diffuse large B-cell lymphoma with odronextamab demonstrated a manageable safety profile and durable responses among patients previously treated with 2 lines of therapy.
In a long-term, real-world analysis, CPX-351 induction therapy was significantly associated with achievement of measurable residual disease status, which was correlated with improved overall survival among patients with high-risk AML.
In a long-term, real-world analysis, CPX-351 induction therapy was significantly associated with achievement of measurable residual disease status, which was correlated with improved overall survival among patients with high-risk AML.
An induction therapy regimen of chidamide with cytarabine, aclarubicin, and G‐CSF (CAG) plus venetoclax-azacitidine for the treatment of acute myeloid leukemia showed efficacy and tolerability in a phase 2 trial.
An induction therapy regimen of chidamide with cytarabine, aclarubicin, and G‐CSF (CAG) plus venetoclax-azacitidine for the treatment of acute myeloid leukemia showed efficacy and tolerability in a phase 2 trial.
FLT3 inhibitors and allogeneic stem cell transplantation were associated with improved survival outcomes for patients diagnosed with FLT3-mutated acute myeloid leukemia, according to a retrospective study.
FLT3 inhibitors and allogeneic stem cell transplantation were associated with improved survival outcomes for patients diagnosed with FLT3-mutated acute myeloid leukemia, according to a retrospective study.
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
